Biocon Financial Statements

Biocon (BIOCON) reported revenue of ₹164.70B in FY2025 with net income of ₹14.29B. Total assets stood at ₹587.97B and free cash flow was ₹19.25B.

Biocon Income Statement

Hover the chart icon for year-over-year change.

FY 2021 – FY 2025

Item	Chart	2021	2022	2023	2024	2025
Revenue		73.60B	81.84B	111.74B	156.21B	164.70B
Cost of Rev. Cost of Revenue		-22.09B	-27.18B	-36.63B	-48.98B	-51.98B
Gross Profit		51.52B	54.66B	75.11B	107.23B	112.72B
SGA Sales, General & Admin		-35.95B	-39.72B	-53.92B	-65.59B	-68.98B
Op. Income Operating Income		11.92B	6.80B	10.06B	25.95B	26.88B
PBT Profit Before Tax		11.47B	9.83B	8.97B	16.09B	18.87B
Net Income		7.41B	7.72B	6.43B	12.98B	14.29B
Dil. Shares Diluted Shares		1.19B	1.20B	1.20B	1.20B	1.20B
Diluted EPS		6.24	5.42	3.87	8.54	8.46

Figures in ₹ — millions (M), billions (B), trillions (T). EPS is earnings per share.

Understanding the Income Statement

The income statement shows Biocon's revenue and expenses over a period. Revenue minus costs gives gross profit; after operating expenses, interest, and taxes, the remainder is net income. Diluted EPS divides net income by all shares that could exist if options and convertibles were exercised.

Biocon Balance Sheet

Hover the chart icon for year-over-year change.

FY 2021 – FY 2025

Item	Chart	2021	2022	2023	2024	2025
Curr. assets Total current assets		76.00B	83.82B	123.34B	151.79B	162.86B
Non-curr. assets Total non-current assets		109.22B	120.12B	397.09B	408.92B	425.11B
Total assets		185.22B	203.94B	520.43B	560.71B	587.97B
Curr. liabilities Total current liabilities		42.10B	38.28B	85.11B	153.59B	143.34B
Non-curr. liab. Total non-current liabilities		58.05B	70.96B	210.43B	154.37B	167.51B
Total liabilities		100.15B	109.24B	295.54B	307.96B	310.85B
Total equity		85.08B	94.70B	224.89B	252.75B	277.13B
Total liab. & eq. Total liabilities & equity		185.22B	203.94B	520.43B	560.71B	587.97B

Figures in ₹ — millions (M), billions (B), trillions (T).

Understanding the Balance Sheet

The balance sheet captures Biocon's financial position at a point in time — what it owns (assets), what it owes (liabilities), and the residual value to shareholders (equity). Total assets always equals total liabilities plus equity.

Biocon Cash Flow Statement

Hover the chart icon for year-over-year change.

FY 2021 – FY 2025

Item	Chart	2021	2022	2023	2024	2025
Net Income		8.46B	7.72B	6.43B	12.98B	14.29B
Operating CF Cash flow Operating Activities		11.60B	11.77B	18.53B	29.54B	40.61B
Capex Investments in PPE		-17.46B	-16.98B	-15.96B	-16.81B	-21.37B
Investing CF Cash flow Investing Activities		-36.25B	-16.99B	-142.82B	-10.05B	-2.34B
Dividend Paid		0	0	-718.00M	-2.03B	-829.00M
Financing CF Cash flow Financing Activities		25.64B	2.42B	130.49B	-23.33B	-18.54B
Cash (start) Cash at beginning of period		8.25B	8.97B	6.54B	13.00B	9.20B
Cash (end) Cash at end of period		8.97B	6.54B	12.95B	9.20B	29.24B
FCF Free Cash Flow		-5.87B	-5.21B	2.57B	12.73B	19.25B

Figures in ₹ — millions (M), billions (B), trillions (T).

Understanding Cash Flow

The cash flow statement tracks how Biocon's cash moves through operations, investing, and financing activities. Free cash flow — operating cash minus capital expenditure — shows what is available to return to shareholders.

Data from audited consolidated filings. For educational purposes only — not investment advice. Last update: Mar-2025